Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...
To further complicate clinicians’ treatment decisions, Padcev-Keytruda has become the new standard of care in first-line metastatic bladder cancer, raising the possibility that some physicians might ...
KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.
ImmunityBio (NasdaqGS:IBRX) completed enrollment early in its pivotal Phase 2 bladder cancer trial for ANKTIVA. Interim analysis showed a statistically significant improvement in complete response ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...
Another immunotherapy has been approved for use in urothelial cancer, the most common type of bladder cancer, in the United States. Avelumab (Bavencio, EMD Serono INc), which is a programmed cell ...
In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) can help predict which bladder cancer patients are at higher risk for ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...
Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results